



*IFW*

1615

PATENT  
ATTORNEY DOCKET NO. 50393/006001

Certificate of Mailing: Date of Deposit: November 3, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sarah Wilcox

Printed name of person mailing correspondence

*Sarah Wilcox*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Kemp et al.	Confirmation No.:	5775
Serial No.:	10/589,227	Art Unit:	1615
Filed:	August 11, 2006	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	WOUND HEALING COMPOSITION		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed with the exception of U.S. patents and U.S. patent application publications. Copies of search reports from corresponding international applications are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed within three months of the filing date of the application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

TOOD ARMSTRONG, Ph.D.  
Reg. No. 54, 590

Date: 3 November 2006

  
for Paul T. Clark  
Reg. No. 30, 162

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Sheet 1 of 2

<b>SUBSTITUTE FORM PTO-1449</b> (MODIFIED)  <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	<b>Attorney Docket No.</b>	50393/006001
	<b>Serial No.</b>	10/589,227
	<b>Applicant</b>	Kemp et al.
	<b>Filing Date</b>	August 11, 2006
	<b>Group</b>	1615
	<b>IDS Filed</b>	November 3, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	2002/0161440	10/31/2002	Son et al.			
	2003/0165482	9/4/2003	Rolland et al.			
	5,591,444	1/7/1997	Boss, Jr.			
	6,124,522	9/26/2000	Schroeder			
	6,699,470	3/2/2004	Ameer et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 242 305	10/21/1987	EP (English Abstract)			
	EP 0 344 924	12/6/1989	EP			
	EP 0 989 866	9/25/2002	EP			
	EP 1 137 380	03/31/2004	EP			
	EP 1 184 040	3/6/2002	EP (English Abstract)			
	EP 1 375 647	1/2/2004	EP			
	DE 10116362	10/10/02	DE			
	RU 2023424	11/30/1994	RU (English Abstract)			
	WO99/15637	4/1/1999	WO			
	WO02/072113	9/19/2002	WO			
	WO03/041568	5/22/2003	WO			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50393/006001
	Serial No.	10/589,227
	Applicant	Kemp et al.
	Filing Date	August 11, 2006
	Group	1615
	IDS Filed	November 3, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Berfield et al., "Insulin-like Growth Factor I (IGF-I) Induces Unique Effects in the Cytoskeleton of Cultured Rat Glomerular Mesangial Cells," <i>The Journal of Histochemistry &amp; Cytochemistry</i> 45: 583-593, 1997.
	Brown et al., "Fibroblast Migration in Fibrin Gel Matrices," <i>American Journal of Pathology</i> 142: 273-283, 1993.
	Clark, "Regulation of Fibroplasia in Cutaneous Wound Repair," <i>The American Journal of the Medical Sciences</i> 306: 42-48, 1993.
	Cullen et al., "The Differential Regulation and Secretion of Proteinases from Fetal and Neonatal Fibroblasts by Growth Factors," <i>Int. J. Biochem. Cell Biol.</i> 29: 241-250, 1997.
	Eckes et al., "Impaired Wound Healing in Embryonic and Adult Mice Lacking Vimentin," <i>Journal of Cell Science</i> 113: 2455-2462, 2000.
	Kessler et al., "Fibroblasts in Mechanically Stressed Collagen Lattices Assume a 'Synthetic' Phenotype," <i>The Journal of Biological Chemistry</i> 276: 36575-36585, 2001.
	Kessler-Becker et al., "Expression of Pro-Inflammatory Markers by Human Dermal Fibroblasts in a Three-Dimensional Culture Model is Mediated by an Autocrine Interleukin-1 Loop," <i>The Biochemical Journal</i> 379: 351-358, 2004.
	Meana et al., "Large Surface of Cultured Human Epithelium Obtained on a Dermal Matrix Based on Live Fibroblast-Containing Fibrin Gels," <i>Burns</i> 24: 621-630, 1998.
	Muhart et al., "Behavior of Tissue-Engineered Skin: A Comparison of a Living Skin Equivalent, Autograft, and Occlusive Dressing in Human Donor Sites," <i>Arch. Dermatol.</i> 135: 913-918, 1999.
	Neidert et al., "Fibrin as an Alternative Biopolymer to Type I Collagen for Tissue-Equivalent Fabrication," <i>Proceedings of the 2001 Bioengineering Conference</i> 50: 215-216, 2001.
	Schäffer et al., "Nitric Oxide, an Autocrine Regulator of Wound Fibroblast Synthetic Function," <i>The Journal of Immunology</i> 158: 2357-2381, 1997.
	Tuan et al., "In Vitro Fibroplasia: Matrix Contraction, Cell Growth, and Collagen Production of Fibroblasts Cultured in Fibrin Gels," <i>Experimental Cell Research</i> 223: 127-134, 1996.
	Whiteside et al., "Heterogeneous Synthetic Phenotype of Cloned Scleroderma Fibroblasts May be Due to Aberrant Regulation in the Synthesis of Connective Tissues," <i>Arthritis and Rheumatism</i> 31: 1221-1229, 1988.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	